SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system,  has received renewed approval from the ...

Both cognitive-behavioral therapy and clinical hypnosis are among the most effective options not involving medication.

BioVie Inc. executives should have disclosed protocol compliance problems affecting its clinical trial for its Alzheimer’s ...

Move means small-cap won't receive an expected payout in the first quarter, creating a cash overhang Sangamo Therapeutics Inc.'s stock tumbled 53% Tuesday to put it on track for its second-biggest one ...

Behavioral Intervention Decreases How Much Pain Affects Daily Activities in People with Dialysis-Dependent Kidney Failure, ...

The battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...

In 2024, the field of myasthenia gravis (MG) saw many developments from clinical trials of new treatments, including ...

EXCLUSIVE - Cruel bladder cancer may have found a determined new adversary after an experimental drug have proven to not only ...

Among people with dialysis-dependent kidney failure, a form of psychological therapy called pain coping skills training ...

The University of California San Francisco (UCSF) is seeking participants for four clinical trials exploring the effects of ...

The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...